Collegium Pharmaceutical (COLL) reported $177.76 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 22.7%. EPS of $1.49 for the same period compares to $1.45 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $172.45 million, representing a surprise of +3.08%. The company delivered an EPS surprise of +4.20%, with the consensus EPS estimate being $1.43.While investors scrutinize revenue and earnings changes year-over-year and how they compa ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.20%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.54 per share when it actually produced earnings of $1.77, delivering a surprise of 14.94%.Over the ...

Q1 2025 Earnings Report May 8, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events ...

Collegium Pharmaceutical (COLL) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 and welcome to the Collegium Pharmaceutical First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note that this conference call is being recorded. I will now turn the call over to Ian Karp, Head of Investor Relations at Collegium. Thank you. You may begin. Speaker1 Thanks, Bria, and we ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State o ...

Exhibit 99.1 Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Rec ...

– Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Collegium Pharmaceutical (COLL) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better t ...

Group 1 - Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 24th Annual Needham Healthcare Conference from April 7-10, 2025 [1] - The fireside chat is scheduled for April 8, 2025, at 9:30 a.m. ET and will be available via live webcast [1] - A replay of the webcast will be accessible on the company's website for 90 days post-presentation [1] Group 2 - Collegium is focused on becoming a leading, diversified biopharmaceutical company aimed at improving the lives of individuals with serious medical conditions [2] - The company has a strong portfolio in responsible pain management medications and has recently acquired Jornay PM®, a treatment for ADHD, marking its entry into neuropsychiatry [2] - Collegium's growth strategy includes expanding its commercial portfolio with Jornay PM as the primary growth driver and managing capital deployment in a disciplined manner [2]

STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids” h ...